{"preliminary_commentary":{"by_channel":{"x_thread":46,"podcast":6,"x_video":4,"youtube":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02951325\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-11-01T15:26:39.675Z","note":"Automated from the 40 newest of 58 indexed sources (Sep 2024 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":40,"text":"- Whether adjuvant radiotherapy should be used for high-risk disease in current practice\n- Whether adjuvant radiotherapy improves overall survival\n- How adjuvant radiotherapy can be integrated with contemporary systemic therapy, including immunotherapy\n\nAlso discussed: toxicity."},"drugs_tested":[],"indication":"postcystectomy muscle-invasive bladder cancer","name":"BART","nct_id":"NCT02951325","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=bart-nct02951325. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"BART","arms":[{"description":"Surgery +/- chemotherapy only\n\n* Surgery (Standard/routine care) Cysto-prostatectomy and pelvic nodal dissection as part of their standard care.\n* Chemotherapy All patients following cysto-prostatectomy (inclusive of those received neo-adjuvant chemotherapy) will receive upto 4 cycles of adjuvant chemotherapy if medically fit for the same. The chemotherapy regimen, doses and schedule will be as per standard institutional practice. No concomitant chemotherapy with radiotherapy is recommended.\n\nNo radiation therapy will be given.","label":"Standard","type":"NO_INTERVENTION"},{"description":"Surgery +/- chemotherapy as per standard arm and Radiation therapy as experimental intervention\n\nRadiation Therapy:\n\nAll patients will be treated with conformal radiotherapy technique with intensity modulated radiotherapy with or without image guidance. The radiotherapy will start within 8 weeks from the date of surgery if adjuvant chemotherapy has not been planned. The radiotherapy will start within 4 weeks from the date of last chemo cycle, in patients who will be given adjuvant chemotherapy.\n\nDose Prescription:\n\n•50.4 Gray (Gy) in 28 fractions (1.8Gy/#) will be prescribed for the nodal PTV. In case of R1 and/or R2 resection dose to the pelvic nodes and tumour bed may be increased to 54-56 Gy in 28 fractions depending on the constraints achieved during planning.\n\nPatient assessments: Clinical assessment for toxicity evaluation and disease status. QOL evaluation of the patients.","label":"Test","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2030-04-13","type":"ESTIMATED"},"conditions":["Bladder Cancer","Urothelial Carcinoma Bladder"],"enrollment":{"count":153,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Adjuvant RT","otherNames":[],"type":"OTHER"}],"last_update":"2025-02-13","lead_sponsor":"Tata Memorial Centre","official_title":"Prospective Randomized Trial of Adjuvant Radiotherapy Following Surgery and Chemotherapy in Muscle Invasive Transitional Cell Carcinoma of Urinary Bladder","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-05-08","type":"ACTUAL"},"primary_outcomes":[{"measure":"Improvement in loco-regional relapse free survival (LRFS)","timeFrame":"2 year"}],"references":[{"citation":"Murthy V, Maitre P, Singh M, Pal M, Arora A, Pujari L, Kapoor A, Pandey H, Sharma R, Gudipudi D, Joshi A, Prabhash K, Noronha V, Menon S, Mehta P, Bakshi G, Prakash G. Study Protocol of the Bladder Adjuvant RadioTherapy (BART) Trial: A Randomised Phase III Trial of Adjuvant Radiotherapy Following Cystectomy in Bladder Cancer. Clin Oncol (R Coll Radiol). 2023 Sep;35(9):e506-e515. doi: 10.1016/j.clon.2023.04.010. Epub 2023 May 5.","pmid":"37208232","type":"BACKGROUND"},{"citation":"Murthy V, Maitre P, Bakshi G, Pal M, Singh M, Sharma R, Gudipudi D, Pujari L, Pandey H, Bandekar B, Joseph D, Krishnatry R, Phurailatpam R, Kannan S, Arora A, Misra A, Joshi A, Noronha V, Prabhash K, Menon S, Prakash G. Bladder Adjuvant Radiation Therapy (BART): Acute and Late Toxicity From a Phase III Multicenter Randomized Controlled Trial. Int J Radiat Oncol Biol Phys. 2025 Mar 1;121(3):728-736. doi: 10.1016/j.ijrobp.2024.09.040. Epub 2024 Sep 29.","pmid":"39353477","type":"RESULT"},{"citation":"Murthy V, Maitre P, Pal M, Arora A, Phurailatpam R, Sharma R, Gudipudi D, Rajappa S, Pujari L, Bandekar B, Joseph D, Kannan S, Krishnatry R, Misra A, Joshi A, Noronha V, Prabhash K, Menon S, Bakshi G, Prakash G. Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer. J Clin Oncol. 2026 Jul;44(19):1812-1821. doi: 10.1200/JCO-25-02093. Epub 2026 May 21.","pmid":"42166701","type":"DERIVED"}],"start_date":{"date":"2016-06-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Bladder Cancer Adjuvant Radiotherapy Trial","url":"https://clinicaltrials.gov/study/NCT02951325"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/bart-nct02951325"}